Lung and Gut Microbiota Changes Associated with Pseudomonas aeruginosa Infection in Mouse Models of Cystic Fibrosis
- PMID: 34830048
- PMCID: PMC8625166
- DOI: 10.3390/ijms222212169
Lung and Gut Microbiota Changes Associated with Pseudomonas aeruginosa Infection in Mouse Models of Cystic Fibrosis
Abstract
Cystic fibrosis (CF) disease leads to altered lung and gut microbiomes compared to healthy subjects. The magnitude of this dysbiosis is influenced by organ-specific microenvironmental conditions at different stages of the disease. However, how this gut-lung dysbiosis is influenced by Pseudomonas aeruginosa chronic infection is unclear. To test the relationship between CFTR dysfunction and gut-lung microbiome under chronic infection, we established a model of P. aeruginosa infection in wild-type (WT) and gut-corrected CF mice. Using 16S ribosomal RNA gene, we compared lung, stool, and gut microbiota of C57Bl/6 Cftr tm1UNCTgN(FABPCFTR) or WT mice at the naïve state or infected with P. aeruginosa. P. aeruginosa infection influences murine health significantly changing body weight both in CF and WT mice. Both stool and gut microbiota revealed significantly higher values of alpha diversity in WT mice than in CF mice, while lung microbiota showed similar values. Infection with P. aeruginosa did not changed the diversity of the stool and gut microbiota, while a drop of diversity of the lung microbiota was observed compared to non-infected mice. However, the taxonomic composition of gut microbiota was shown to be influenced by P. aeruginosa infection in CF mice but not in WT mice. This finding indicates that P. aeruginosa chronic infection has a major impact on microbiota diversity and composition in the lung. In the gut, CFTR genotype and P. aeruginosa infection affected the overall diversity and taxonomic microbiota composition, respectively. Overall, our results suggest a cross-talk between lung and gut microbiota in relation to P. aeruginosa chronic infection and CFTR mutation.
Keywords: CFTR mice; Pseudomonas aeruginosa; animal models; cystic fibrosis; gut; gut-lung axis; lung; microbiome.
Conflict of interest statement
The authors declare no conflict of interest. The funders had no role in the design of the study, in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8625166/bin/ijms-22-12169-g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8625166/bin/ijms-22-12169-g002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8625166/bin/ijms-22-12169-g003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8625166/bin/ijms-22-12169-g004.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8625166/bin/ijms-22-12169-g005.gif)
Similar articles
-
Mouse models of chronic lung infection with Pseudomonas aeruginosa: models for the study of cystic fibrosis.Pediatr Pulmonol. 2000 Nov;30(5):413-24. doi: 10.1002/1099-0496(200011)30:5<413::aid-ppul8>3.0.co;2-9. Pediatr Pulmonol. 2000. PMID: 11064433 Review.
-
The altered gut microbiota in adults with cystic fibrosis.BMC Microbiol. 2017 Mar 9;17(1):58. doi: 10.1186/s12866-017-0968-8. BMC Microbiol. 2017. PMID: 28279152 Free PMC article.
-
Cystic fibrosis mouse model-dependent intestinal structure and gut microbiome.Mamm Genome. 2015 Jun;26(5-6):222-34. doi: 10.1007/s00335-015-9560-4. Epub 2015 Feb 27. Mamm Genome. 2015. PMID: 25721416 Free PMC article.
-
Transgenic cystic fibrosis mice exhibit reduced early clearance of Pseudomonas aeruginosa from the respiratory tract.J Immunol. 2001 Jun 15;166(12):7410-8. doi: 10.4049/jimmunol.166.12.7410. J Immunol. 2001. PMID: 11390493
-
Cystic fibrosis lung environment and Pseudomonas aeruginosa infection.BMC Pulm Med. 2016 Dec 5;16(1):174. doi: 10.1186/s12890-016-0339-5. BMC Pulm Med. 2016. PMID: 27919253 Free PMC article. Review.
Cited by
-
The Hydroxypyridinone Iron Chelator DIBI Reduces Bacterial Load and Inflammation in Experimental Lung Infection.Biomedicines. 2024 Jun 29;12(7):1452. doi: 10.3390/biomedicines12071452. Biomedicines. 2024. PMID: 39062025 Free PMC article.
-
Effect of beta-glucan supplementation on cystic fibrosis colonic microbiota: an in vitro study.Pediatr Res. 2024 May;95(6):1519-1527. doi: 10.1038/s41390-023-02944-0. Epub 2023 Dec 13. Pediatr Res. 2024. PMID: 38092964
-
Host tracheal and intestinal microbiomes inhibit Coccidioides growth in vitro.bioRxiv [Preprint]. 2023 Oct 23:2023.10.23.563655. doi: 10.1101/2023.10.23.563655. bioRxiv. 2023. Update in: Microbiol Spectr. 2024 Jul 2;12(7):e0297823. doi: 10.1128/spectrum.02978-23. PMID: 37961490 Free PMC article. Updated. Preprint.
-
Probiotics Administration in Cystic Fibrosis: What Is the Evidence?Nutrients. 2022 Jul 30;14(15):3160. doi: 10.3390/nu14153160. Nutrients. 2022. PMID: 35956335 Free PMC article. Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous